The market for trastuzumab in the US is becoming increasingly crowded with Merck & Co. today launching Samsung Bioepis’ Ontruzant (trastuzumab-dttb) in two strengths, representing the fifth biosimilar to Genentech’s Herceptin available in the country, at a discount competitive with those offered by several other biosimilar players.
Merck’s approval and launch of the biosimilar, which marks Samsung Bioepis’ first oncology biosimilar in the US, spans all eligible...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?